In the murine sepsis model, a single intraperitoneal administration (multiplicity of infection = 10) conferred 100% survival, significantly reduced bacterial loads in the liver and kidneys, and attenuated systemic inflammation compared to treatment with polymyxin B. Histopathological analyses further confirmed the protective effects of AbpL and its favorable safety profile.<h4>Discussion</h4>Owing to its strong lytic activity, environmental stability, and robust <i>in vitro</i> and <i>in vivo</i> efficacy, AbpL represents a highly promising candidate for the treatment of MDR-AB infections. This evidence concerns the gene FLNC and infection.